Preimplantation Genetics Diagnosis (PGD) Market By Test Type (Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030
The global preimplantation genetic diagnosis (PGD) market size was valued at $81.52 million in 2020, and is projected to reach $217.18 million by 2030, registering a CAGR of 10.3% from 2021 to 2030. Preimplantation genetic diagnosis (PGD) is called as embryo screening. It is a branch of genetics that involves genetic testing of embryos through in vitro fertilization (IVF).
PGD eliminates risk of selective pregnancy termination for couples who are at substantial risk of transferring serious genetic, chromosomal, or hereditary disorders, including spinal muscular atrophy and cystic fibrosis.
PGD provides effective solution for healthy embryos free from genetic, hereditary, and chromosomal disorders. It is an evolving technique in modern genetic study. In addition, increase in prevalence of hereditary, chromosomal, and genetic disorders every year that include triploidy, thalassemia, and Duchenne muscular dystrophy (DMD)requires PGD for the diagnosis of mutational changes. Moreover, increase in usage of PGD techniques in selecting human leukocyte antigen (HLA) profile to match existing sibling with disease and sex balancing in family spurred the growth of PGD market. Furthermore, growth in infertility rate and increase in awareness regarding PGD technique boost the growth of the market.
The global PGD market is segmented on the basis of test type and region. By test type, the market is classified into chromosomal abnormalities, aneuploidy, X-linked diseases, single gene disorders, HLA typing, gender selection, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major players operating in the global market have adopted key strategies such as product launch to strengthen their market outreach and sustain the stiff competition in the market.
COMPETITION ANALYSIS
The major market participants profiled in this report include Agilent Technologies, Inc., CeGaT GmbH, Illumina Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Natera Inc., PacGenomics, PerkinElmer, Inc., Quest Diagnostics Inc., and Reproductive Genetic Innovations (RGI)
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the preimplantation genetics diagnosis market analysis from 2020 to 2030 to identify the prevailing preimplantation genetics diagnosis market opportunity.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the preimplantation genetics diagnosis (pgd) market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
The key players within preimplantation genetics diagnosis industry are profiled in this report and their strategies are analyzed thoroughly, which help understand the competitive outlook of the preimplantation genetics diagnosis industry.
The report includes the analysis of the regional as well as global preimplantation genetics diagnosis market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Test Type
Chromosomal Abnormalities
Aneuploidy
X-linked diseases
Single Gene Disorders
HLA Typing
Gender selection
Others
By Region
Asia-Pacific
China
Japan
India
South Korea
Rest Of Asia Pacific
LAMEA
Latin America
Middle East
Africa
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Rest of Europe
Key Market Players
Agilent Technologies, Inc.
cegat gmbh
Illumina Inc.
Invitae Corporation
Laboratory Corporation of America Holdings
Natera Inc.
pacgenomics
PerkinElmer, Inc.
Quest Diagnostics Inc.
Reproductive Genetic Innovations (RGI)
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Chromosomal Abnormalities
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Aneuploidy
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 X-linked diseases
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Single Gene Disorders
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- 4.6 HLA Typing
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market analysis by country
- 4.7 Gender selection
- 4.7.1 Key market trends, growth factors and opportunities
- 4.7.2 Market size and forecast, by region
- 4.7.3 Market analysis by country
- 4.8 Others
- 4.8.1 Key market trends, growth factors and opportunities
- 4.8.2 Market size and forecast, by region
- 4.8.3 Market analysis by country
- CHAPTER 5: PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY REGION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Asia-Pacific
- 5.2.1 Key trends and opportunities
- 5.2.2 Asia-Pacific Market size and forecast, by Test Type
- 5.2.3 Asia-Pacific Market size and forecast, by country
- 5.2.3.1 China
- 5.2.3.1.1 Market size and forecast, by Test Type
- 5.2.3.2 Japan
- 5.2.3.2.1 Market size and forecast, by Test Type
- 5.2.3.3 India
- 5.2.3.3.1 Market size and forecast, by Test Type
- 5.2.3.4 South Korea
- 5.2.3.4.1 Market size and forecast, by Test Type
- 5.2.3.5 Rest Of Asia Pacific
- 5.2.3.5.1 Market size and forecast, by Test Type
- 5.3 LAMEA
- 5.3.1 Key trends and opportunities
- 5.3.2 LAMEA Market size and forecast, by Test Type
- 5.3.3 LAMEA Market size and forecast, by country
- 5.3.3.1 Latin America
- 5.3.3.1.1 Market size and forecast, by Test Type
- 5.3.3.2 Middle East
- 5.3.3.2.1 Market size and forecast, by Test Type
- 5.3.3.3 Africa
- 5.3.3.3.1 Market size and forecast, by Test Type
- 5.4 North America
- 5.4.1 Key trends and opportunities
- 5.4.2 North America Market size and forecast, by Test Type
- 5.4.3 North America Market size and forecast, by country
- 5.4.3.1 U.S.
- 5.4.3.1.1 Market size and forecast, by Test Type
- 5.4.3.2 Canada
- 5.4.3.2.1 Market size and forecast, by Test Type
- 5.4.3.3 Mexico
- 5.4.3.3.1 Market size and forecast, by Test Type
- 5.5 Europe
- 5.5.1 Key trends and opportunities
- 5.5.2 Europe Market size and forecast, by Test Type
- 5.5.3 Europe Market size and forecast, by country
- 5.5.3.1 Germany
- 5.5.3.1.1 Market size and forecast, by Test Type
- 5.5.3.2 France
- 5.5.3.2.1 Market size and forecast, by Test Type
- 5.5.3.3 U.K.
- 5.5.3.3.1 Market size and forecast, by Test Type
- 5.5.3.4 Italy
- 5.5.3.4.1 Market size and forecast, by Test Type
- 5.5.3.5 Rest of Europe
- 5.5.3.5.1 Market size and forecast, by Test Type
- CHAPTER 6: COMPANY LANDSCAPE
- 6.1. Introduction
- 6.2. Top winning strategies
- 6.3. Product Mapping of Top 10 Player
- 6.4. Competitive Dashboard
- 6.5. Competitive Heatmap
- 6.6. Key developments
- CHAPTER 7: COMPANY PROFILES
- 7.1 Agilent Technologies, Inc.
- 7.1.1 Company overview
- 7.1.2 Company snapshot
- 7.1.3 Operating business segments
- 7.1.4 Product portfolio
- 7.1.5 Business performance
- 7.1.6 Key strategic moves and developments
- 7.2 cegat gmbh
- 7.2.1 Company overview
- 7.2.2 Company snapshot
- 7.2.3 Operating business segments
- 7.2.4 Product portfolio
- 7.2.5 Business performance
- 7.2.6 Key strategic moves and developments
- 7.3 Illumina Inc.
- 7.3.1 Company overview
- 7.3.2 Company snapshot
- 7.3.3 Operating business segments
- 7.3.4 Product portfolio
- 7.3.5 Business performance
- 7.3.6 Key strategic moves and developments
- 7.4 Invitae Corporation
- 7.4.1 Company overview
- 7.4.2 Company snapshot
- 7.4.3 Operating business segments
- 7.4.4 Product portfolio
- 7.4.5 Business performance
- 7.4.6 Key strategic moves and developments
- 7.5 Laboratory Corporation of America Holdings
- 7.5.1 Company overview
- 7.5.2 Company snapshot
- 7.5.3 Operating business segments
- 7.5.4 Product portfolio
- 7.5.5 Business performance
- 7.5.6 Key strategic moves and developments
- 7.6 Natera Inc.
- 7.6.1 Company overview
- 7.6.2 Company snapshot
- 7.6.3 Operating business segments
- 7.6.4 Product portfolio
- 7.6.5 Business performance
- 7.6.6 Key strategic moves and developments
- 7.7 pacgenomics
- 7.7.1 Company overview
- 7.7.2 Company snapshot
- 7.7.3 Operating business segments
- 7.7.4 Product portfolio
- 7.7.5 Business performance
- 7.7.6 Key strategic moves and developments
- 7.8 PerkinElmer, Inc.
- 7.8.1 Company overview
- 7.8.2 Company snapshot
- 7.8.3 Operating business segments
- 7.8.4 Product portfolio
- 7.8.5 Business performance
- 7.8.6 Key strategic moves and developments
- 7.9 Quest Diagnostics Inc.
- 7.9.1 Company overview
- 7.9.2 Company snapshot
- 7.9.3 Operating business segments
- 7.9.4 Product portfolio
- 7.9.5 Business performance
- 7.9.6 Key strategic moves and developments
- 7.10 Reproductive Genetic Innovations (RGI)
- 7.10.1 Company overview
- 7.10.2 Company snapshot
- 7.10.3 Operating business segments
- 7.10.4 Product portfolio
- 7.10.5 Business performance
- 7.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
- TABLE 2. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR CHROMOSOMAL ABNORMALITIES, BY REGION , 2020-2030,($THOUSAND)
- TABLE 3. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET CHROMOSOMAL ABNORMALITIES BY COUNTRY, 2020-2030,($THOUSAND)
- TABLE 4. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR ANEUPLOIDY, BY REGION , 2020-2030,($THOUSAND)
- TABLE 5. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET ANEUPLOIDY BY COUNTRY, 2020-2030,($THOUSAND)
- TABLE 6. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR X-LINKED DISEASES, BY REGION , 2020-2030,($THOUSAND)
- TABLE 7. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET X-LINKED DISEASES BY COUNTRY, 2020-2030,($THOUSAND)
- TABLE 8. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR SINGLE GENE DISORDERS, BY REGION , 2020-2030,($THOUSAND)
- TABLE 9. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET SINGLE GENE DISORDERS BY COUNTRY, 2020-2030,($THOUSAND)
- TABLE 10. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR HLA TYPING, BY REGION , 2020-2030,($THOUSAND)
- TABLE 11. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET HLA TYPING BY COUNTRY, 2020-2030,($THOUSAND)
- TABLE 12. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR GENDER SELECTION, BY REGION , 2020-2030,($THOUSAND)
- TABLE 13. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET GENDER SELECTION BY COUNTRY, 2020-2030,($THOUSAND)
- TABLE 14. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($THOUSAND)
- TABLE 15. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET OTHERS BY COUNTRY, 2020-2030,($THOUSAND)
- TABLE 16. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY REGION, 2020-2030,($THOUSAND)
- TABLE 17. ASIA-PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
- TABLE 18. ASIA-PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)
- TABLE 19. CHINA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
- TABLE 20. JAPAN PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
- TABLE 21. INDIA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
- TABLE 22. SOUTH KOREA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
- TABLE 23. REST OF ASIA PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
- TABLE 24. LAMEA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
- TABLE 25. LAMEA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)
- TABLE 26. LATIN AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
- TABLE 27. MIDDLE EAST PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
- TABLE 28. AFRICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
- TABLE 29. NORTH AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
- TABLE 30. NORTH AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)
- TABLE 31. U.S. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
- TABLE 32. CANADA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
- TABLE 33. MEXICO PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
- TABLE 34. EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY TEST TYPE, 2020-2030,($THOUSAND)
- TABLE 35. EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET, BY COUNTRY, 2020-2030,($THOUSAND)
- TABLE 36. GERMANY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
- TABLE 37. FRANCE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
- TABLE 38. U.K. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
- TABLE 39. ITALY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
- TABLE 40. REST OF EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY TEST TYPE 2020-2030,($THOUSAND)
- TABLE 41.AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
- TABLE 42.AGILENT TECHNOLOGIES, INC.: OPERATING SEGMENTS
- TABLE 43.AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
- TABLE 44.AGILENT TECHNOLOGIES, INC.: NET SALES,
- TABLE 45.AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
- TABLE 46.CEGAT GMBH: COMPANY SNAPSHOT
- TABLE 47.CEGAT GMBH: OPERATING SEGMENTS
- TABLE 48.CEGAT GMBH: PRODUCT PORTFOLIO
- TABLE 49.CEGAT GMBH: NET SALES,
- TABLE 50.CEGAT GMBH: KEY STRATERGIES
- TABLE 51.ILLUMINA INC.: COMPANY SNAPSHOT
- TABLE 52.ILLUMINA INC.: OPERATING SEGMENTS
- TABLE 53.ILLUMINA INC.: PRODUCT PORTFOLIO
- TABLE 54.ILLUMINA INC.: NET SALES,
- TABLE 55.ILLUMINA INC.: KEY STRATERGIES
- TABLE 56.INVITAE CORPORATION: COMPANY SNAPSHOT
- TABLE 57.INVITAE CORPORATION: OPERATING SEGMENTS
- TABLE 58.INVITAE CORPORATION: PRODUCT PORTFOLIO
- TABLE 59.INVITAE CORPORATION: NET SALES,
- TABLE 60.INVITAE CORPORATION: KEY STRATERGIES
- TABLE 61.LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
- TABLE 62.LABORATORY CORPORATION OF AMERICA HOLDINGS: OPERATING SEGMENTS
- TABLE 63.LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
- TABLE 64.LABORATORY CORPORATION OF AMERICA HOLDINGS: NET SALES,
- TABLE 65.LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATERGIES
- TABLE 66.NATERA INC.: COMPANY SNAPSHOT
- TABLE 67.NATERA INC.: OPERATING SEGMENTS
- TABLE 68.NATERA INC.: PRODUCT PORTFOLIO
- TABLE 69.NATERA INC.: NET SALES,
- TABLE 70.NATERA INC.: KEY STRATERGIES
- TABLE 71.PACGENOMICS: COMPANY SNAPSHOT
- TABLE 72.PACGENOMICS: OPERATING SEGMENTS
- TABLE 73.PACGENOMICS: PRODUCT PORTFOLIO
- TABLE 74.PACGENOMICS: NET SALES,
- TABLE 75.PACGENOMICS: KEY STRATERGIES
- TABLE 76.PERKINELMER, INC.: COMPANY SNAPSHOT
- TABLE 77.PERKINELMER, INC.: OPERATING SEGMENTS
- TABLE 78.PERKINELMER, INC.: PRODUCT PORTFOLIO
- TABLE 79.PERKINELMER, INC.: NET SALES,
- TABLE 80.PERKINELMER, INC.: KEY STRATERGIES
- TABLE 81.QUEST DIAGNOSTICS INC.: COMPANY SNAPSHOT
- TABLE 82.QUEST DIAGNOSTICS INC.: OPERATING SEGMENTS
- TABLE 83.QUEST DIAGNOSTICS INC.: PRODUCT PORTFOLIO
- TABLE 84.QUEST DIAGNOSTICS INC.: NET SALES,
- TABLE 85.QUEST DIAGNOSTICS INC.: KEY STRATERGIES
- TABLE 86.REPRODUCTIVE GENETIC INNOVATIONS (RGI): COMPANY SNAPSHOT
- TABLE 87.REPRODUCTIVE GENETIC INNOVATIONS (RGI): OPERATING SEGMENTS
- TABLE 88.REPRODUCTIVE GENETIC INNOVATIONS (RGI): PRODUCT PORTFOLIO
- TABLE 89.REPRODUCTIVE GENETIC INNOVATIONS (RGI): NET SALES,
- TABLE 90.REPRODUCTIVE GENETIC INNOVATIONS (RGI): KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET SEGMENTATION
- FIGURE 2.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030
- FIGURE 3.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 11.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,BY TEST TYPE,2020(%)
- FIGURE 12.COMPARATIVE SHARE ANALYSIS OF CHROMOSOMAL ABNORMALITIES PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANEUPLOIDY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF X-LINKED DISEASES PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF SINGLE GENE DISORDERS PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HLA TYPING PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF GENDER SELECTION PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OTHERS PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030(%)
- FIGURE 19.PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET BY REGION,2020
- FIGURE 20.CHINA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
- FIGURE 21.JAPAN PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
- FIGURE 22.INDIA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
- FIGURE 23.SOUTH KOREA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
- FIGURE 24.REST OF ASIA PACIFIC PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
- FIGURE 25.LATIN AMERICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
- FIGURE 26.MIDDLE EAST PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
- FIGURE 27.AFRICA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
- FIGURE 28.U.S. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
- FIGURE 29.CANADA PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
- FIGURE 30.MEXICO PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
- FIGURE 31.GERMANY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
- FIGURE 32.FRANCE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
- FIGURE 33.U.K. PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
- FIGURE 34.ITALY PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
- FIGURE 35.REST OF EUROPE PREIMPLANTATION GENETICS DIAGNOSIS (PGD) MARKET,2020-2030($THOUSAND)
- FIGURE 36. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 39.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 40.COMPETITIVE DASHBOARD
- FIGURE 41.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 42.AGILENT TECHNOLOGIES, INC..: NET SALES ,($THOUSAND)
- FIGURE 43.CEGAT GMBH.: NET SALES ,($THOUSAND)
- FIGURE 44.ILLUMINA INC..: NET SALES ,($THOUSAND)
- FIGURE 45.INVITAE CORPORATION.: NET SALES ,($THOUSAND)
- FIGURE 46.LABORATORY CORPORATION OF AMERICA HOLDINGS.: NET SALES ,($THOUSAND)
- FIGURE 47.NATERA INC..: NET SALES ,($THOUSAND)
- FIGURE 48.PACGENOMICS.: NET SALES ,($THOUSAND)
- FIGURE 49.PERKINELMER, INC..: NET SALES ,($THOUSAND)
- FIGURE 50.QUEST DIAGNOSTICS INC..: NET SALES ,($THOUSAND)
- FIGURE 51.REPRODUCTIVE GENETIC INNOVATIONS (RGI).: NET SALES ,($THOUSAND)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook